TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells by unknown
POSTER PRESENTATION Open Access
TLR8 agonist VTX-2337 enhances
NKG2D-mediated cytotoxicity of NK cells
Hailing Lu1*, Yi Yang1, Veronika Groh2, Thomas Spies2, Gregory Dietsch3, Maura Matthews3, Mary L Disis1,
Robert Hershberg3
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
NK cells express an array of activating and inhibitory
receptors, which facilitate the recognition and lysis of
virally infected and transformed cells, but safeguard
healthy cells from attack. NKG2D is an activating recep-
tor expressed on the surface of NK cells that recognizes
the ligands MICA/B and ULBP in human, which can be
expressed on tumor cells or virus-infected cells. While
NKG2D-mediated NK cell cytotoxicity plays an impor-
tant role in tumor immune surveillance, cancer patients
have been reported to have decreased expression and
reduced function of the NKG2D receptor. We hypothe-
size that VTX-2337, a selective TLR8 agonist that acti-
vates myeloid DC and stimulates the production of pro-
inflammatory cytokines including IL-12 and IL-18, may
enhance NK cell function through NKG2D. PBMC from
11 donors were stimulated plate-bound anti-NKG2D
antibody (clone 1D11), with or without prior incubation
with VTX-2337 (500 nM, 24 hr). VTX-2337 significantly
enhanced NKG2D-stimulated IFN-g production and
CD107a expression, as assessed by FACS. To further
investigate the impact of TLR8 activation on NKG2D-
mediated cytotoxicity, VTX-2337-treated PBMC were
incubated with human lymphoblastoid cell line C1R
transfected with the NKG2D ligand, MICA. Pre-activa-
tion of PBMCs with VTX-2337 enhanced the lysis of
C1R-MICA cells. Collectively these data suggest that the
TLR8 agonist VTX-2337 can enhance NK cell-mediated
immune surveillance against cancer through NKG2D
and the recognition of MICA.
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